Sofosbuvir/Velpatasvir — Discount Pricing

Other medications in Infectious Disease

• Trimethoprim
• Amoxicillin
• Azithromycin
• Bictegravir/Emtricitabine/TAF
• Ciprofloxacin
• Dolutegravir/Lamivudine
• Elbasvir/Grazoprevir
• Emtricitabine/Tenofovir

About Sofosbuvir/Velpatasvir

Sofosbuvir velpatasvir is a revolutionary combination medication that has transformed hepatitis C treatment into a manageable, highly effective therapy. This direct-acting antiviral drug offers cure rates exceeding 95% for many patients. At TheDrugClub, we make this life-changing medication accessible by eliminating co-pays and offering convenient home delivery for our members.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Sofosbuvir/Velpatasvir is approved for (FDA label)

Sofosbuvir and velpatasvir is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection [see Dosage and Administration (2.2 , 2.3 , 2.4 ) and Clinical Studies (14) ] : without cirrhosis or with compensated cirrhosis with decompensated cirrhosis for use in combination with ribavirin.

Source: Read the full FDA label on DailyMed. Label effective date: March 6, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Sofosbuvir/Velpatasvir (FDA label)

WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with sofosbuvir and velpatasvir. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated [see Warnings and Precautions (5.1) ] . WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV See full prescribing information for complete boxed warning. Hepatitis B virus (HBV) reactivation has been reported, in some cases resulting in fulminant hepatitis, hepatic failure, and death. ( 5.1 )

Source: FDA prescribing information (DailyMed). Set ID: d0c1a945-4440-4b5c-81aa-693ed3db597c. SPL document ID: 314b9ef7-c6e5-44c9-9fbf-b0d35a24cd7d. Label effective date: March 6, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Sofosbuvir/Velpatasvir (FDA label)

Each sofosbuvir and velpatasvir tablet contains 400 mg of sofosbuvir and 100 mg of velpatasvir. The tablets are pink, diamond-shaped, film-coated, and debossed with "ASE" on one side and "9761" on the other side. Tablets: 400 mg of sofosbuvir and 100 mg of velpatasvir. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: d0c1a945-4440-4b5c-81aa-693ed3db597c. SPL document ID: 314b9ef7-c6e5-44c9-9fbf-b0d35a24cd7d. Label effective date: March 6, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Sofosbuvir/Velpatasvir (FDA label)

The following serious adverse reactions are described below and elsewhere in labeling: Serious Symptomatic Bradycardia When Coadministered with Amiodarone [see Warnings and Precautions (5.2) ]. The most common adverse reactions (incidence greater than or equal to 10%, all grades) observed in adults and pediatric subjects 6 years of age and older with treatment with sofosbuvir and velpatasvir for 12 weeks are headache and fatigue. ( 6.1 ) The most common adverse reactions (incidence greater than or equal to 10%, grade 1 or 2) observed in pediatric subjects less than 6 years of age are vomiting and product use issue (spitting up the drug). ( 6.1 ) The most common adverse reactions (incidence greater than or equal to 10%, all grades) observed with treatment with sofosbuvir and velpatasvir and ribavirin for 12 weeks in adult patients with decompensated cirrhosis are fatigue, anemia, nausea, headache, insomnia, and diarrhea. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Asegua Therapeutics at 1-800-445-3235 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: d0c1a945-4440-4b5c-81aa-693ed3db597c. SPL document ID: 314b9ef7-c6e5-44c9-9fbf-b0d35a24cd7d. Label effective date: March 6, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Sofosbuvir/Velpatasvir (FDA label)

Sofosbuvir and velpatasvir and ribavirin combination regimen is contraindicated in patients for whom ribavirin is contraindicated. Refer to the ribavirin prescribing information for a list of contraindications for ribavirin [see Dosage and Administration (2.2 , 2.3 , 2.4) ]. Sofosbuvir and velpatasvir and ribavirin combination regimen is contraindicated in patients for whom ribavirin is contraindicated. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: d0c1a945-4440-4b5c-81aa-693ed3db597c. SPL document ID: 314b9ef7-c6e5-44c9-9fbf-b0d35a24cd7d. Label effective date: March 6, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.